Abstracts tagged "Outcome measures"

Abstract Number: 0324 • ACR Convergence 2020
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
Courtney Stull¹, Soumya Reddy², M. Elaine Husni³, Jose Scher⁴, Ethan Craig¹, Jessica Walsh⁵ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Cleveland Clinic, Cleveland, OH, ⁴NYU School of Medicine, New York City, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome…
Abstract Number: 0727 • ACR Convergence 2020
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
Naveen R¹, Namita Mohindra¹, Neeraj Jain¹ and Amita Aggarwal², ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
Abstract Number: 1157 • ACR Convergence 2020
Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed for a Median of Fifteen Years
Sara Alehashemi¹, Megha Garg², Kim Johnson³, Kelly King⁴, Chris Zalewski⁴, Debbie Payne⁵, Adriana de Jesus⁶, Joseph Snow⁷, Wadih Zein⁵, M. Teresa Magone⁵, Rachel Bishop⁸, Carmen Brewer⁴, Jeff Kim⁴, Scott Paul⁹, John Butman¹⁰ and Raphaela Goldbach-Mansky¹¹, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ²NIH/NIAID, Rochester, NY, ³NIH, NIAID, Bethesda, ⁴NIH, NIDCD, Bethesda, MD, ⁵NIH/NEI, Bethesda, MD, ⁶Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁷NIH, NIMH, Bethesda, MD, ⁸NIH, NEI, Bethesda, MD, ⁹NIH, CC/RMD, Bethesda, MD, ¹⁰NIH, CC/DRD, Bethesa, MD, ¹¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Patients (pts) with NOMID have systemic inflammation and organ damage such as sensorineural hearing loss, hydrocephalus, optic nerve atrophy and growth plate defects. IL-1 blocking…
Abstract Number: 1668 • ACR Convergence 2020
Long-Term Outcomes in Children Born to Anti-Ro and/or Anti-La Positive Mothers
Talia Diaz¹, Daniela Dominguez², Edgar Jaeggi³, Andrea Knight⁴, Carl A. Laskin⁵, Lawrence Ng⁶, Franklin Silverio¹, Earl D. Silverman⁷ and Linda Hiraki⁸, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ³Fetal Cardiac Program, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Neonatal Lupus Erythematosus (NLE) is an acquired autoimmune disorder associated with the transplacental passage of maternal anti-Ro and/or anti-La antibodies. Previous studies have suggested…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 0167 • ACR Convergence 2020
Rheumatoid Arthritis Patient Phenotypes from a Digital Health Coaching Engagement Program
Jonathan Patterson¹, Kirby Magid², Dhiren Patel³ and Matt Allison³, ¹Pack Health, Birmingham, AL, ²University of North Carolina at Charlotte, Charlotte, ³Pack Health, Birmingham
Background/Purpose: The goal of this study was to examine whether cluster analysis could be used to identify homogeneous subgroups of engagement in RA patients enrolled…
Abstract Number: 0338 • ACR Convergence 2020
Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis
Eugenia Chen¹ and Maida Wong², ¹Department of Medicine, University of California Irvine, Orange, CA, ²Division of Rheumatology, Department of Medicine, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that involves musculoskeletal and skin manifestations. Such autoimmune disease has been associated with increased lymphoproliferative disease…
Abstract Number: 0728 • ACR Convergence 2020
Clinical Outcomes of Juvenile Arthritis in Adulthood: A Systematic Review
Lily Siok Hoon Lim¹, Woo Jin Kim², Yushi Wang² and Kaien Gu³, ¹University of Manitoba, Children's Hospital of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba Max Rady College of Medicine, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Juvenile arthritis (JA) is the most common pediatric rheumatic disease, with potentially permanent functional impacts on patients long after initial diagnosis. Little is known…
Abstract Number: 1164 • ACR Convergence 2020
Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients
Katelin R. Honer¹, Kim Johnson¹, Gema Souto Adeva¹, Gina Montealegre Sanchez², Jenna Wade³, Jacob Mitchell¹, Katherine Townsend³, Adriana de Jesus⁴ and Raphaela Goldbach-Mansky⁵, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Rockville, MD, ³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁵Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Monogenic autoinflammatory diseases (AID) are caused by innate immune dysregulation resulting in systemic inflammation and variable organ-specific clinical manifestations. The Translational Autoinflammatory Disease Section…
Abstract Number: 1696 • ACR Convergence 2020
Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative
Stephen Bender¹, Michael Weinblatt² and Daniel Duch¹, ¹FACTORx, Cherry Hill, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medical claims data have been used since 2008 to measure the implementation of the diagnostic and referral strategies resulting from participation in RAPID® CME…
Abstract Number: 1899 • ACR Convergence 2020
Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Zhixiu Li¹, Mohammad Khan², Sjef van der Linden³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Matthew Brown⁷ and Muhammad Khan⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Kent State University, Kent, OH, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁸Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: To investigate life expectancy of a Swiss cohort of patients with ankylosing spondylitis (AS) versus general population during 35 years of longitudinal follow up,…
Abstract Number: 0168 • ACR Convergence 2020
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Uwe Pleyer¹, Salem Almutairi², Conor Murphy³, Rola Hamam⁴, Karina Julian⁵, Shereen Hammad⁶, Orsolya Nagy⁷, Zohar Habot-Wilner⁸, Zsuzsanna Szepessy⁹, Yan Guex-Crosier¹⁰ and Sofia Androudi¹¹, ¹Charité Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Germany, ²Al-Bahar Ophthalmology Center - Al-Sabah Hospital, Kuwait City, Kuwait, ³Royal Victoria Eye & Ear Hospital, Dublin, Ireland, ⁴American University of Beirut, Beirut, Lebanon, ⁵Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁶AbbVie Biopharmaceuticals GmbH, Dubai, United Arab Emirates, ⁷AbbVie Kft, Budapest, Hungary, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland, ¹¹University of Thessaly, Larissa, Greece
Background/Purpose: VISUAL clinical trials demonstrated efficacy and safety of adalimumab (ADA) in patients with active and inactive non-infectious, intermediate, posterior, or panuveitis (NIIPPU).1-3 The purpose…
Abstract Number: 0339 • ACR Convergence 2020
Is Sex-adjusted Treatment in Early-PsA Justified?
Evangelia Passia¹, Jolanda Luime¹, Marc Kok², Ilja Tchetverikov³, Marijn Vis⁴, Fouchia Fodili⁵, Yvonne Ruiterman⁶ and Lindy-Anne Korswagen⁷, ¹Erasmus MC, Rotterdam, ²Maasstadziekenhuis, Rotterdam, ³Albert Schweitzer Ziekenhuis, Dordrecht, ⁴Erasmus UMC, Rotterdam, Netherlands, ⁵RZWN, Roosendaal, ⁶HAGA ziekenhuis, Den Haag, ⁷Franciscus Gasthuis, Rotterdam
Background/Purpose: According to existing knowledge, the prevalence of psoriatic arthritis (PsA) is equal in men and women, however, women experience a higher burden of disease…
Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 1173 • ACR Convergence 2020
No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Maria Teresa Terreri⁵, Edoardo Marrani⁶, Tadej Avcin⁷, Maria Katsicas⁸, Dana Nemcova⁹, Maria Jose Santos¹⁰, Jürgen Brunner¹¹, Tilmann Kallinich¹², Mikhail Kostik¹³, Kirsten Minden¹⁴, Anjali Patwardhan¹⁵, Kathryn Torok¹⁶ and Nicola Helmus¹⁷, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²German Rheumatism Research Center, Berlin, Germany, ³PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁴Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁵Federal University of São Paulo, São Paulo, Brazil, ⁶University of Florence, Firenze, Italy, ⁷Ljubljana University Medical Centre, Ljubljana, Slovenia, ⁸Hospital de Pediatria, Buenos Aires, Argentina, ⁹General University Hospital, Prague, Czech Republic, ¹⁰Hospital Garcia de Orta, Almada, Portugal, ¹¹Tirol Kliniken, Innsbruck, Innsbruck, Austria, ¹²Charite, Berlin, Germany, ¹³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁵University of Missouri, Columbia, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. Longitudinal prospective follow up data of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].